AA
JNCE

ALPS Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

ALPS Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-28,212
Closed -$66K – 1100
2022
Q3 		$66K Sell
28,212
-2,444
-8% -$8.65K ﹤0.01% 1036
2022
Q2 		$93K Sell
30,656
-22,468
-42% -$109K ﹤0.01% 1026
2022
Q1 		$361K Sell
53,124
-6,174
-10% -$44K ﹤0.01% 611
2021
Q4 		$495K Buy
+59,298
New +$489K 0.01% 502
2018
Q4 		– Sell
-57,738
Closed -$375K – 965
2018
Q3 		$375K Buy
57,738
+10,600
+22% +$78.8K ﹤0.01% 882
2018
Q2 		$361K Buy
47,138
+3,999
+9% +$57.7K ﹤0.01% 821
2018
Q1 		$964K Buy
43,139
+7,497
+21% +$166K 0.01% 319
2017
Q4 		$454K Buy
35,642
+3,966
+13% +$58.3K ﹤0.01% 638
2017
Q3 		$494K Buy
31,676
+2,644
+9% +$37.4K ﹤0.01% 546
2017
Q2 		$407K Buy
+29,032
New +$621K ﹤0.01% 676

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

ALPS Advisors's JNCE Position: Q4 2022 in Review

ALPS Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 28,212 shares — an estimated $66K sold.

ALPS Advisors first reported a position in JNCE in Q2 2017 and held it in 10 quarters. The position peaked at $964K in Q1 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

  • ALPS Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • ALPS Advisors sold 28,212 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $66K.
  • ALPS Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 10 quarters.
  • ALPS Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $964K in Q1 2018.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.